Melbourne, June 18, 2026, 02:12 AEST
- CSL closed Wednesday at A$106.79, rising 0.51%. Shares moved between A$105.42 and A$107.48 during the day.
- The S&P/ASX 200 added 0.54% to finish at 8,966.30. The move gave the stock a stronger market setting.
- CSL’s May reset stays in focus for investors. Lower guidance for FY26 is on the table, further non-cash impairments totaling around $5 billion are still ahead, and full-year results land Aug. 18.
CSL Ltd finished a bit stronger in the last ASX session, ending at A$106.79 on Wednesday with the Australian cash market already outside its standard hours at the dateline. ASX normal trading goes from around 09:59:45 to 16:00 Sydney time.
CSL isn’t trading as a typical defensive healthcare stock anymore. It’s being seen as a turnaround play. The stock is up 7.36% from last week’s close. Shares are still down 38.76% for the year and 55.82% for FY2026.
S&P/ASX 200 hit a two-month high Wednesday, boosted by gains in 138 stocks as the broader market rose. Energy shares slipped after oil prices fell. CSL managed a small gain on a day with stronger risk buying.
CSL did not put out any new operating updates in the last day. The company’s ASX filings show its most recent announcement was a June 9 cessation of securities. Earlier in June, there were director-interest and substantial-holder filings.
Company leaders are sticking with the May 11 reset story. Interim CEO Gordon Naylor told investors the “financial benefits will take longer” after the company finished a 90-day review, which lowered the 2026 outlook and pushed focus back onto execution.
CSL is guiding to FY26 revenue of around $15.2 billion and NPATA near $3.1 billion on a constant-currency basis, taking out FX impacts. NPATA stands for net profit after tax before amortisation and big one-off costs. CSL also signaled about $5 billion more in non-cash pre-tax impairments—accounting write-downs—spread across FY26 and FY27.
CSL shares plunged 16% to finish at A$100.75 in May after the company issued a warning about an added impairment charge and trimmed its outlook, ABC reported. At one point, the stock dropped under A$100, hitting a ten-year low.
CSL still looks cheap to Morningstar’s Lochlan Halloway, who says the next big thing for the stock is seeing real cuts in blood plasma collection costs. He notes that competition remains tough: Sanofi is a strong player in influenza vaccines, and Roche’s Hemlibra competes in haemophilia. On top of that, plasma products keep seeing more pricing pressure.
But the rebound can run into trouble. CSL’s review points to U.S. immunoglobulin inventory pressure, China albumin prices, HEMGENIX sales ramp, iron rivals and Middle East disruption. Immunoglobulin drugs are antibody medicines from plasma. If revenue still trails demand, the stock’s latest bounce could falter.
CSL’s next hard catalyst is its full-year results and final dividend on Aug. 18. In the meantime, the stock may move on whether Naylor’s cost and portfolio work shows up in actual numbers instead of just a better narrative.
